Interactive Features

Quiz

Treating Acute Myeloid Leukemia With Aspacytarabine

03/05/2024

True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.

True or False: Aspacytarabine...

03/05/2024

Oncology

Quiz

Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML

02/15/2024

True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...

True or False: Fractionated...

02/15/2024

Oncology

Quiz

Humanized Bispecific Antibody Vibecotamab for R/R AML

02/07/2024

True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.

True or False: Administering...

02/07/2024

Oncology

Quiz

Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy

01/10/2024

True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...

True or False: According to...

01/10/2024

Oncology

Quiz

Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML

12/09/2023

A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...

A fludarabine-based regimen did...

12/09/2023

Oncology

Quiz

Sorafenib Maintenence After AlloHSCT For FLT3-ITD-Mutated AML

12/04/2023

True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...

True or False: Results from a...

12/04/2023

Oncology

Quiz

Azacitidine, Venetoclax, and Pevonedistat Combination for Secondary AML, MDS, or CMML

11/09/2023

True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.

True or False: The triplet...

11/09/2023

Oncology

Quiz

Treating AML With Gemtuzumab Ozogamicin Plus Intensive Chemotherapy

09/26/2023

True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.

True or False: Findings from a...

09/26/2023

Oncology

Quiz

Treating R/R AML With Venetoclax, Azacitidine, and Homoharringtonine

09/11/2023

According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.

According to a phase 2 trial,...

09/11/2023

Oncology

Quiz

Quizartinib for Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3/ITD Mutations

08/03/2023

True or False: The FDA approved quizartinib with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for patients with newly diagnosed acute...

True or False: The FDA approved...

08/03/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology